Bayer appoints Dr. Christoph Koenen, MD, as Chief Medical Officer
Not intended for U.S. and UK Media
Berlin, October 1, 2026 – Bayer today announced the appointment of Dr. Christoph Koenen, MD, as Chief Medical Officer, effective October 1, 2026. He will lead medical and scientific strategies across the organization and assume these …
BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA
Not intended for UK Media
U.S. FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy / EU EMA designations are for treating syndromic and non-syndromic inherited retinal disorders (IRDs) of the rod-dominant phenotype and non-syndromic IRDs of the …
Bayer Launches New Menopause Advocacy and Policy Alliance
Not intended for U.S. and UK Media – International Menopause Society (IMS) Congress 2026:
Global leaders in women’s and public health unite to form the Menopause Advocacy and Policy (MAP) Alliance and accelerate menopause care, policy and workplace support / At IMS, the MAP Alliance unveils research that highlights why menopause must …
Bayer’s Lynkuet™ (elinzanetant) granted priority review by U.S. FDA for additional indication
Not intended for U.S. and UK Media
Priority review granted for treatment of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) in women undergoing endocrine therapy for hormone receptor positive breast cancer / LynkuetTM (elinzanetant) also became the first …
Bayer places 2 billion euro hybrid bonds
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Dual tranche with non-call periods of six and nine years
New blister receives RecyClass Design for Recycling certification, with phased rollout planned across 11 additional European markets in 2026–2027
Robigo’s engineered microbes for combatting Sudden Death Syndrome in soybeans match the performance of commercially available chemistries at half the cost, targeting launch in 2028 / The second product in development, targeting the #1 fungal …
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
Not intended for U.S. and UK Media
Kerendia™ is the first FDA-approved treatment option in more than 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D) / Approval addresses an important unmet need for a population at increased risk of …
U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
Accelerated approval of sevabertinib for patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) follows FDA Priority Review and Breakthrough Therapy Designations, and reflects the potential for sevabertinib to provide substantial …
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel
Bayer initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation
Not intended for U.S. and UK Media
GIRK4 (BAY 3670549) is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor being evaluated as a potential new approach to control the electrical activity of cardiomyocytes in patients …